Novo Nordisk transfers Parkinson's cell therapy to Cellular Intelligence, which is supported by Zuckerberg.
Novo will acquire an equity interest in Cellular Intelligence and is set to receive future milestone payments and royalties. The startup intends to utilize its AI platform for STEM-PD, a stem-cell-based treatment that Novo halted last October.
On Monday, the companies announced that Novo Nordisk has transferred STEM-PD, an experimental stem-cell therapy for Parkinson's disease, to Cellular Intelligence, an AI biotech supported by Mark Zuckerberg.
The financial details were not revealed. Novo will take a stake in the startup and will be eligible for future payments related to milestones and royalties. Novo discontinued the therapy last October when it closed its cell-therapy division as part of a larger restructuring effort.
STEM-PD is an allogeneic, stem-cell-derived treatment aimed at replacing dopamine-producing nerve cells that are diminished in Parkinson's disease. It was in the early stages of clinical development at Novo before the closure of the unit.
Cellular Intelligence indicated that it plans to leverage its proprietary AI platform to expedite the program, enhance manufacturing capabilities, and lower production costs.
Cellular Intelligence has raised over $60 million to date from investors, including Khosla Ventures and the Chan Zuckerberg Initiative, the philanthropic foundation of Mark Zuckerberg and Priscilla Chan. This deal highlights a trend of significant investments from CZI into AI-driven biological innovations in recent months.
For Novo, this transaction resolves a remaining aspect of the restructuring that took place last October, which focused on strengthening the company's obesity and diabetes segments following increased demand for Wegovy and Ozempic that surpassed supply levels.
The cell-therapy division was primarily engaged in early-stage research rather than commercial operations; its closure has allowed for reallocation of engineering and manufacturing resources for GLP-1 production.
Recently, Novo reported that Wegovy accounted for 65% of new prescriptions in the U.S., with sales in obesity care increasing by 22% on a constant-currency basis.
For Cellular Intelligence, this agreement provides the company with a clinical-stage asset to support its AI platform strategy. STEM-PD is well-characterized, having progressed through preclinical and early clinical phases thanks to Novo's initial funding.
The startup will now combine its in-development therapy with the cost and efficiency advantages promised by its AI platform when presenting to potential investors.
There is currently no public timeline for the next clinical milestone, and Cellular Intelligence has not disclosed when it anticipates filing an IND amendment or what specific dose-finding work it will inherit from Novo's previous program.
Parkinson's disease impacts approximately 10 million individuals globally. Various research teams have sought treatments to replace the lost dopamine-producing cells for decades; Cellular Intelligence's strategy is to demonstrate that AI-driven manufacturing and dose selection can render such treatments commercially feasible in a timeframe that surpasses traditional cell-therapy projects.
The companies did not specify whether Novo's equity stake grants it observer rights, intellectual property back-licensing options, or any operational involvement at Cellular Intelligence. The agreement is effective immediately.
Other articles
Fervo Energy, backed by Bill Gates, has increased its IPO target to $1.82 billion, with a valuation of $7.4 billion.
The geothermal company Fervo Energy has increased its US IPO target to as high as $1.82 billion, up from the previous amount of $1.33 billion, according to a filing with the SEC made on Monday.
Novo Nordisk transfers Parkinson's cell therapy to Cellular Intelligence, which is backed by Zuckerberg.
Novo Nordisk has transferred its Parkinson's cell therapy, STEM-PD, which was previously on hold, to the AI biotech company Cellular Intelligence in exchange for equity and milestone payments.
A $13,500 Unitree robot was 'blessed' at the Jogyesa Temple in Seoul.
A Unitree robot was 'blessed' at the Jogyesa Temple in Seoul. Amidst the event, the Jogye Order established five AI ethics guidelines that are worth considering.
Fervo Energy, backed by Bill Gates, has increased its IPO target to $1.82 billion with a valuation of $7.4 billion.
The geothermal developer Fervo Energy has increased its US IPO target to a maximum of $1.82 billion, up from the previous $1.33 billion, according to a filing with the SEC on Monday.
Santa Clara County files a lawsuit against Meta concerning fraudulent advertisements on Facebook and Instagram.
Santa Clara County has filed a lawsuit against Meta regarding fraudulent advertisements on Facebook and Instagram, claiming that these scams generate up to $7 billion in annual revenue.
A $13,500 Unitree robot was 'blessed' at the Jogyesa Temple in Seoul.
A Unitree robot was 'blessed' at the Jogyesa Temple in Seoul. Amid the event, the Jogye Order established five AI ethics guidelines that are worth considering.
Novo Nordisk transfers Parkinson's cell therapy to Cellular Intelligence, which is supported by Zuckerberg.
Novo Nordisk has transferred STEM-PD, an unused Parkinson's cell therapy, to the AI biotech Cellular Intelligence in exchange for equity and certain milestones.